Biological Products, Except Diagnostic Substances (Biotech) - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the Biological industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

Biological Products, Except Diagnostic Substances (Biotech) - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - Biological Products, Except Diagnostic Substances (Biotech)
Corporate Insider Buy Sell Ratio (Insider Count) - Biological Products, Except Diagnostic Substances (Biotech)
Biological Products, Except Diagnostic Substances (Biotech) - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2026-04-17 ZIVO / ZIVO Bioscience, Inc. 4 STROME MARK E By entity P - Purchase I 2.00 100,000
2026-04-17 CGON / CG Oncology, Inc. 4 Mulay James M - Exercise D 36.63 15,600
2026-04-17 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 8.46 14,722
2026-04-17 AGEN / Agenus Inc. 4 ARMEN GARO H A - Award D 4.79 3,403
2026-04-17 MGTX / MeiraGTx Holdings plc 4 PERCEPTIVE ADVISORS LLC A - Award I 9.00 555,555
2026-04-16 AURA / Aura Biosciences, Inc. 4 Kilroy Conor S - Sale D 7.02 -11,738
2026-04-16 APGE / Apogee Therapeutics, Inc. 4 Henderson Jane S - Sale D 90.00 -2,000
2026-04-16 ALEC / Alector, Inc. 4 Wong-Sarad Grace S - Sale D 2.65 -1,820
2026-04-16 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE S - Sale D 14.18 -19,060
2026-04-16 SRRK / Scholar Rock Holding Corporation 4 Sinha Vikas S - Sale D 49.5745 -10,410
2026-04-16 SRRK / Scholar Rock Holding Corporation 4 Vaishnaw Akshay S - Sale D 49.5745 -12,246
2026-04-16 SRRK / Scholar Rock Holding Corporation 4 Woods Keith S - Sale D 49.5745 -10,220
2026-04-16 SRRK / Scholar Rock Holding Corporation 4 Hallal David S - Sale D 49.5745 -30,615
2026-04-16 CGTX / Cognition Therapeutics, Inc. 4 Ricciardi Lisa P - Purchase D 1.10 9,175
2026-04-16 CGTX / Cognition Therapeutics, Inc. 4 Doyle John Brendan P - Purchase D 1.13 10,000
2026-04-16 CGTX / Cognition Therapeutics, Inc. 4 Caggiano Anthony P - Purchase D 1.11 10,000
2026-04-16 APGE / Apogee Therapeutics, Inc. 4 HENDERSON MICHAEL THOMAS M - Exercise D 22.86 3,000
2026-04-16 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 8.46 14,722
2026-04-15 KYMR / Kymera Therapeutics, Inc. 4 Booth Bruce S - Sale I 90.10 -385
2026-04-15 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE S - Sale D 14.61 -19,060
2026-04-15 KYMR / Kymera Therapeutics, Inc. 4 Booth Bruce S - Sale I 90.10 -2,750
2026-04-15 KYMR / Kymera Therapeutics, Inc. 4 Booth Bruce S - Sale D 89.95 -2,200
2026-04-15 GILD / Gilead Sciences, Inc. 4 Dickinson Andrew D S - Sale D 140.96 -3,000
2026-04-15 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G S - Sale D 90 -1,300
2026-04-15 VOR / Vor Biopharma Inc. 4 RA CAPITAL MANAGEMENT, LLC See footnotes S - Sale I 16.01 -53,644
2026-04-15 GILD / Gilead Sciences, Inc. 4 Mercier Johanna S - Sale D 140.96 -3,000
2026-04-15 RVMD / Revolution Medicines, Inc. 4 GOLDSMITH MARK A S - Sale D 150.0874 -120,000
2026-04-15 KOD / Kodiak Sciences Inc. 4 BORGESON JOHN A. M - Exercise D 1.04 28,614
2026-04-15 RVMD / Revolution Medicines, Inc. 4 GOLDSMITH MARK A M - Exercise D 4.09 23,244
2026-04-15 RVMD / Revolution Medicines, Inc. 4 GOLDSMITH MARK A M - Exercise D 4.73 96,756
2026-04-15 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 8.46 14,722
2026-04-15 KYMR / Kymera Therapeutics, Inc. 4 Booth Bruce M - Exercise D 14.18 2,200
2026-04-15 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G M - Exercise D 43.5 1,300
2026-04-14 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G S - Sale D 90.0016 -5,251
2026-04-14 KYMR / Kymera Therapeutics, Inc. 4 Booth Bruce S - Sale D 89.97 -4,159
2026-04-14 CGEN / Compugen Ltd. 4 Levine Zurit S - Sale D 2.80 -2,000
2026-04-14 VOR / Vor Biopharma Inc. 4 RA CAPITAL MANAGEMENT, LLC See footnotes S - Sale I 15.97 -153,735
2026-04-14 KYMR / Kymera Therapeutics, Inc. 4 Goodman Noah S - Sale D 90 -1,347
2026-04-14 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE S - Sale D 14.56 -19,060
2026-04-14 CGEN / Compugen Ltd. 4 Ophir Eran S - Sale D 2.9042 -5,000
2026-04-14 GLUE / Monte Rosa Therapeutics, Inc. 4 Warmuth Markus S - Sale D 17.6406 -8,000
2026-04-14 TWST / Twist Bioscience Corporation 4 Laponis Adam S - Sale D 55 -3,000
2026-04-14 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 8.46 14,722
2026-04-14 CGEN / Compugen Ltd. 4 Levine Zurit M - Exercise D 1.15 2,000
2026-04-14 CGEN / Compugen Ltd. 4 Ophir Eran M - Exercise D 0.8292 5,000
2026-04-14 TECH / Bio-Techne Corporation 4 Kelderman Kim M - Exercise D 36,500
2026-04-14 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G M - Exercise D 43.5 785
2026-04-14 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G M - Exercise D 30.17 4,466
2026-04-14 KYMR / Kymera Therapeutics, Inc. 4 Booth Bruce M - Exercise D 14.18 4,159
2026-04-14 TECH / Bio-Techne Corporation 4 Kelderman Kim F - Taxes D 58.66 -32,088
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)